| Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma EE Bar, A Chaudhry, A Lin, X Fan, K Schreck, W Matsui, S Piccirillo, ... Stem cells 25 (10), 2524-2533, 2007 | 766 | 2007 |
| The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance KC Schreck, P Taylor, L Marchionni, V Gopalakrishnan, EE Bar, N Gaiano, ... Clinical cancer research 16 (24), 6060-6070, 2010 | 201 | 2010 |
| The exon junction complex component Magoh controls brain size by regulating neural stem cell division DL Silver, DE Watkins-Chow, KC Schreck, TJ Pierfelice, DM Larson, ... Nature neuroscience 13 (5), 551-558, 2010 | 190 | 2010 |
| BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors KC Schreck, SA Grossman, CA Pratilas Cancers 11 (9), 1262, 2019 | 124 | 2019 |
| Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas KC Schreck, S Ranjan, N Skorupan, C Bettegowda, CG Eberhart, ... Journal of neuro-oncology 143, 87-93, 2019 | 98 | 2019 |
| Notch, neural stem cells, and brain tumors TJ Pierfelice, KC Schreck, CG Eberhart, N Gaiano Cold Spring Harbor symposia on quantitative biology 73, 367-375, 2008 | 93 | 2008 |
| Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System. KC Schreck, SA Grossman Oncology (08909091) 32 (11), 2018 | 79 | 2018 |
| Notch signaling promotes growth and invasion in uveal melanoma L Asnaghi, KB Ebrahimi, KC Schreck, EE Bar, ML Coonfield, WR Bell, ... Clinical cancer research 18 (3), 654-665, 2012 | 77 | 2012 |
| Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers J Naidoo, KC Schreck, W Fu, C Hu, A Carvajal-Gonzalez, RM Connolly, ... Journal for immunotherapy of cancer 9 (8), 2021 | 48 | 2021 |
| Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients EQ Lee, M Weller, J Sul, SJ Bagley, S Sahebjam, M Van Den Bent, ... Neuro-oncology 22 (5), 601-612, 2020 | 45 | 2020 |
| Subgroup and subtype-specific outcomes in adult medulloblastoma H Coltin, L Sundaresan, KS Smith, P Skowron, L Massimi, CG Eberhart, ... Acta neuropathologica 142 (5), 859-871, 2021 | 44 | 2021 |
| Concurrent BRAF/MEK inhibitors in BRAF V600–mutant high-grade primary brain tumors KC Schreck, A Guajardo, DDM Lin, CG Eberhart, SA Grossman Journal of the National Comprehensive Cancer Network 16 (4), 343-347, 2018 | 44 | 2018 |
| Notch3 activation promotes invasive glioma formation in a tissue site-specific manner TJ Pierfelice, KC Schreck, L Dang, L Asnaghi, N Gaiano, CG Eberhart Cancer research 71 (3), 1115-1125, 2011 | 42 | 2011 |
| Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma SA Grossman, KC Schreck, K Ballman, B Alexander Neuro-oncology 19 (4), 469-474, 2017 | 39 | 2017 |
| Clinical response to bevacizumab in schwannomatosis J Blakeley, KC Schreck, DG Evans, BR Korf, D Zagzag, MA Karajannis, ... Neurology 83 (21), 1986-1987, 2014 | 38 | 2014 |
| Feasibility and biological activity of a ketogenic/intermittent-fasting diet in patients with glioma KC Schreck, FC Hsu, A Berrington, B Henry-Barron, D Vizthum, L Blair, ... Neurology 97 (9), e953-e963, 2021 | 31 | 2021 |
| Modulation of the Voltage Sensor of L-type Ca2+ Channels by Intracellular Ca2+ D Isaev, K Solt, O Gurtovaya, JP Reeves, R Shirokov The Journal of general physiology 123 (5), 555-571, 2004 | 29 | 2004 |
| Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma KC Schreck, A Morin, G Zhao, AN Allen, P Flannery, M Glantz, AL Green, ... Clinical Cancer Research 27 (22), 6197-6208, 2021 | 24 | 2021 |
| Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma KC Schreck, AN Allen, J Wang, CA Pratilas Neuro-Oncology Advances 2 (1), vdaa138, 2020 | 23 | 2020 |
| Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma P Odeniyide, ME Yohe, K Pollard, AV Vaseva, A Calizo, L Zhang, ... Oncogene 41 (21), 2973-2983, 2022 | 20 | 2022 |
